This site is intended for Healthcare professionals only.

Lupin gets EIR from USFDA for Pithampur unit

Lupin gets EIR from USFDA for Pithampur unit

Lupin said its Pithampur Unit-3 facility is involved in the manufacture of metered dose inhalers (MDis), dry powder inhalers (DPis) and topical formulations for the regulated markets.

New Delhi: Drug major Lupin Ltd Tuesday announced receipt of the Establishment Inspection Report (EIR) from the US health regulator for its Pithampur facility in Madhya Pradesh.

The US Food and Drug Administration (USFDA) gives EIR on closure of inspection of an establishment that is the subject of USFDA or USFDA-contracted inspection.

The following two tabs change content below.
Farhat Nasim

Farhat Nasim

Farhat Nasim joined Medical Dialogue as Reporter in 2017. She Covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She is a graduate of St.Xavier's College Ranchi. She can be contacted at Contact no. 011-43720751

Source: PTI
0 comment(s) on Lupin gets EIR from USFDA for Pithampur unit

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted